Ephedrine
Market, By Dosage Form (Tablets, Capsules, and Injections), By Disease
Indication (Bronchial Asthma, Spinal Anesthesia induced Hypotension, and
Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Others), and By Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019
- 2027
Ephedrine is a decongestant and
bronchodilator, used to treat bronchospasms caused due to asthma. The medicine
reduces the swelling and constricts the blood vessels in the nasal passages
which widens the lung airways and allows the patient to breathe easily. Due to
the medicine’s central nervous system stimulatory effects, ephedrine is also
used extensively during spinal anesthesia in order to prevent intra-operative
hypotension. The medicine is available in the form of tablets, capsules and
injections.
Global Ephedrine Market –
Dynamics
High prevalence of hypotension
during spinal anesthesia is expected to propel growth of the ephedrine market
over the forecast period. For instance, according to the Columbian Journal of
Anesthesiology, 2018, incidences of hypotension during spinal anesthesia ranges
from 1.9% to 71% globally.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3320
Moreover, launches and approvals
of ephedrine products is expected to boost the ephedrine market growth over the
forecast period. For instance, in January 2017, Par Pharmaceutical, a
subsidiary of Endo International plc, received approval from the U.S. Food and
Drug Administration (FDA) for its new ephedrine sulfate injection, CORPHEDRA.
The injection will be used to for the treatment of hypotension occurring in the
process of spinal anesthesia.
However, restrictions on
ephedrine usage through regulatory authorities is expected to restrain the
market over the forecast period. For instance, since 2001, the Government of
Canada has authorized ephedrine only as a nasal decongestant with a maximum
dosage of 8mg along with 32mg in a 24 hour period.
Global Ephedrine Market –
Regional Insights
North America accounted for the
largest market share in 2018, owing to launches and approvals of new ephedrine
products in the region. For instance, in March 2017, Akorn, Inc., a developer
and manufacturer of generics and branded prescription pharmaceuticals, received
the U.S. Food and Drug Administration (FDA) approval for its New Drug
Application (NDA) for single dose ampule of an ephedrine sulfate injection
which is indicated for treating hypotension occurring during spinal anesthesia.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/ephedrine-market-3320
Increasing ephedrine product
launches is expected to propel the market growth in the Europe region. For
instance, in April 2016, Avadel Pharmaceuticals, formerly known as Flamel
Technologies, received approval from the U.S. Food and Drug Administration for
Akovaz, an ephedrine sulfate injection, which will be used to treat hypotension
occurring during anesthesia.
Moreover, high prevalence of
hypotension during spinal anesthesia in Asia Pacific is likely to drive the
ephedrine market over the forecast period. For instance, according to a study
published in the Indian Journal of Anesthesia, 2018, the cases of mild,
moderate, and severe spinal anesthesia induced hypotension was approximately 20%,
35%, and 40% respectively.
Global Ephedrine Market –
Competitive Landscape
Key player operating in the
market include Servier, Merck Sharp & Dohme Corp., Amgen Inc., Sanofi S.A.,
Avadel Pharmaceuticals, GlaxoSmithKline plc, Endo Pharmaceuticals plc, and
Akorn Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3320
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment